RCKT Key Statistics, Chart & Performance
The current stock price of RCKT is 3.32 USD. In the past month the price increased by 2.79%. In the past year, price decreased by -76.1%.
RCKT Latest News, Press Relases and Analysis
RCKT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About RCKT
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Company Info
ROCKET PHARMACEUTICALS INC
9 Cedarbrook Drive
Cranbury NEW JERSEY 08512 US
CEO: Gaurav Shah
Employees: 299
Phone: 16464409100
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What does RCKT do?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 299 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
What is the stock price of ROCKET PHARMACEUTICALS INC today?
The current stock price of RCKT is 3.32 USD. The price decreased by -2.92% in the last trading session.
Does ROCKET PHARMACEUTICALS INC pay dividends?
RCKT does not pay a dividend.
How is the ChartMill rating for ROCKET PHARMACEUTICALS INC?
RCKT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting RCKT stock to perform?
21 analysts have analysed RCKT and the average price target is 8.03 USD. This implies a price increase of 141.94% is expected in the next year compared to the current price of 3.32.
Can you provide the upcoming earnings date for ROCKET PHARMACEUTICALS INC?
ROCKET PHARMACEUTICALS INC (RCKT) will report earnings on 2026-02-25, after the market close.
RCKT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RCKT. When comparing the yearly performance of all stocks, RCKT is a bad performer in the overall market: 92.18% of all stocks are doing better.
RCKT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RCKT. Both the profitability and financial health of RCKT have multiple concerns.
RCKT Financial Highlights
Over the last trailing twelve months RCKT reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS increased by 19.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.46% | ||
| ROE | -76.8% | ||
| Debt/Equity | 0.06 |
RCKT Forecast & Estimates
21 analysts have analysed RCKT and the average price target is 8.03 USD. This implies a price increase of 141.94% is expected in the next year compared to the current price of 3.32.
For the next year, analysts expect an EPS growth of 22.11% and a revenue growth -100% for RCKT